Therefore, it is not surprising that the majority of clinical cancer biomarkers are glycoproteins, such as alpha-fetoprotein for liver cancer, cancer antigen 125 for ovarian cancer, carcinoembryonic antigen for colon cancer, and prostate-specific antigen for prostate cancer [6–9]. This evidence concerns the gene KLK3 and cancer.